dehydrochloromethyltestosterone

Dehydrochloromethyltestosterone is a synthetic anabolic–androgenic steroid (AAS) developed in the 1960s by Jenapharm and marketed as Oral Turinabol. It is a derivative of metandienone (dehydromethyltestosterone) with a chlorine atom at the 4th carbon position, which inhibits aromatization to estrogen and reduces androgenic activity. The drug acts primarily as an agonist of the androgen receptor, promoting increased protein synthesis and nitrogen retention in muscle tissue, leading to enhanced lean body mass and bone mineral density. It was historically used for performance enhancement but lacks robust clinical trial data for approved medical indications[2][5][8].

Brand names

Oral TurinabolTurinabol

Other names

chlorodehydromethyltestosterone4-chlorodehydromethyltestosterone4-chloromethandienone